PMCB

PharmaCyte Biotech, Inc. Common Stock

0.69

USD

PMCB Earnings Reports

Positive Surprise Ratio

PMCB beat 2 of 4 last estimates.

50%

Next Report

Date of Next Report

Mar 16, 2026

Estimate for Q3 26 (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q3 25 (Revenue/ EPS)

PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue

On Dec 12, 2025, PMCB reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Guardian Pharmacy Services, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.25

Actual

$0.37

Surprise

+45.10%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.45

Actual

-$0.42

Surprise

+6.77%

Esperion Therapeutics, Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.24

Actual

$0.22

Surprise

-10.46%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Zevra Therapeutics, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

$0.05

Actual

$0.21

Surprise

+311.76%

SIGA Technologies Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

Actual

-$0.08

Surprise

Nature's Sunshine Products Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.19

Actual

$0.30

Surprise

+54.80%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.25

Surprise

+13.49%

Corbus Pharmaceuticals Holdings, Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$1.60

Actual

-$1.25

Surprise

+22.24%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.51

Surprise

+37.05%

FAQ

What were PharmaCyte Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, PharmaCyte Biotech, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to PharmaCyte Biotech, Inc. Common Stock's Q2 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is PharmaCyte Biotech, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 16, 2026.

What are the forecasts for PharmaCyte Biotech, Inc. Common Stock's next earnings report?

Based on -- analysts, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.